Scarica l'app Stockscreener
3.80
0.00%
0.00
Precedente Chiudi:
$3.80
Aprire:
$3.8
Volume 24 ore:
886
Relative Volume:
0.07
Capitalizzazione di mercato:
$69.50M
Reddito:
-
Utile/perdita netta:
$-12.63M
Rapporto P/E:
-5.4739
EPS:
-0.6942
Flusso di cassa netto:
$-12.18M
1 W Prestazione:
-1.20%
1M Prestazione:
-4.52%
6M Prestazione:
-0.78%
1 anno Prestazione:
-15.27%
Intervallo 1D:
$3.80
$3.80
Intervallo di 1 settimana:
$3.70
$3.84
Portata 52W:
$2.74
$7.28
Genenta Science Spa Adr Stock (GNTA) Company Profile
Nome
Genenta Science Spa Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GNTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.80 | 69.50M | 0 | -12.63M | -12.18M | -0.6942 |
|
VRTX
Vertex Pharmaceuticals Inc
|
375.63 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.80 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.10 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
672.35 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.29 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-06-29 | Ripresa | ROTH MKM | Buy |
| 2022-07-25 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-13 | Iniziato | Maxim Group | Buy |
Genenta Science Spa Adr Borsa (GNTA) Ultime notizie
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar - GlobeNewswire Inc.
Genenta secures $21.9 million for cancer drug trial By Investing.com - Investing.com South Africa
Genenta secures €20M in mandatory convertible bond deal - Investing.com India
Genenta secures €20M in mandatory convertible bond deal By Investing.com - Investing.com South Africa
Genenta secures $21.9 million for cancer drug trial - Investing.com India
Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research - TipRanks
Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development - TipRanks
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
Genenta Science Announces Shareholder Meeting - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
10 Best Italian Stocks To Buy Now - Yahoo Finance
Genenta Science Spa Adr Azioni (GNTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):